CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
LX6171 High Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00691808
NCT00691808Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI)

Lexicon Pharmaceuticals·interventional·Posted Jun 5, 2008·Updated Mar 3, 2010

In Brief

A Phase 2 clinical trial evaluating LX6171 High Dose, LX6171 Low Dose, and 1 other intervention for Age-Related Memory Disorders. Completed, enrolled 103 participants across 2 sites.

Detailed Summary

The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Memory Disorders
CountriesNetherlands
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2008
Enrollment StartFeb 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.1 years ago

Interventions

LX6171 High Dosedrug

A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

LX6171 Low Dosedrug

A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

Placebodrug

Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.